| Outcome Measures: |
Primary: Change in the microvascular complications of type 2 diabetes, specifically diabetic kidney disease, These outcome will be measured through the glomerular filtration rate (GFR), (MDRD-1 equation: GFR (expressed in ml/min/1.73 m2), and Albuminuria (ACR (mg/g)., baseline at 1 month before the intervention and 3, 6, 9, 12, 15, 18, 21, 24, 27, 30, 33, 36 month after intervention|Change in the microvascular complications of type 2 diabetes, specifically Retinopathy., This will be measured through assessment by ophthalmologist., baseline at 1 month before the intervention, 12 y 24 month after intervention|Change in the microvascular complications of type 2 diabetes, specifically peripheral and sympathic neuropathy., This will be measured through assessment nerve conduction, sensory nerve conduction, motor nerve conduction, sympathic skin response., baseline at 1 month before the intervention, 12, 24 y 36 month | Secondary: Assessment of the optimization of the metabolic control, defined by the International Diabetes Federation, This will be measured through haemoglobin A1c (HbA1c) (%), continuous glucose monitoring, blood pressure (mmhg), total cholesterol (mg/dL), HDL (mg/dL), LDL (mg/dL), triglycerides (mg/dL)., baseline at 1 month before the intervention and 3, 6, 9, 12, 15, 18, 21, 24, 27, 30, 33, 36 month after the intervention|Assessment of treatment complications, This will be measured through the record of all treatment complications like: Infection or surgical bleeding, inflammation of the veins for drug administration, temporary digestive disorders, gastroesophageal reflux disease, or acute retention of urine infection, prolonged pain in the area of operation. Specifically for the Gastric Bypass, intestinal fistulas poor healing of sutures, nutritional deficiencies, excessive weight loss. Less often marginal ulcerative lesions and intestinal obstruction. In the other side, the sleeve gastrectomy: dehiscence of the suture line and nutritional complications., 1, 3, 6, 9, 12, 15, 18, 21, 24, 27, 30, 33, 36 month after intervention|Assessment of the quality of life., This will be measured through the Diabetes Quality of Life Questionnaire., baseline at 1 month before the intervention and 3, 6, 12, and 24 month after the intervention|Assessment of macrovascular events, This will be measured through the record of all macrovascular events, like cardiovascular deaths, nonfatal myocardial infarction, cardiovascular interventions, nonfatal stroke, amputation or surgery for peripheral atherosclerotic artery disease., baseline at 1 month before the intervention and 1, 3, 6, 9, 12, 15, 18, 21, 24, 27, 30, 33, 36 month after the intervention|How many patients not requiring antidiabetic agents, This will be measured through the record of number of patient who requiring oral antidiabetic agent, number of patient who requiring insulin, and both., baseline 1 month after intervention, and at 6, 12, 18, 24, 30, and 36 month after intervention
|
